Covered recipient · General Payments record
MATTHEW D MILLER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$5,839.14
- Reported across 235 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,400.74 | 57 |
| Education | $99.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $199.39 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $123.29 | 5 |
| E.R. Squibb & Sons, L.L.C. | $83.18 | 4 |
| Gilead Sciences, Inc. | $74.69 | 3 |
| Genentech USA, Inc. | $72.28 | 3 |
| Incyte Corporation | $72.21 | 3 |
| BTG INTERNATIONAL, INC. | $61.70 | 1 |
| GENZYME CORPORATION | $58.57 | 2 |
| Acerta Pharma LLC | $58.10 | 3 |
| ARRAY BIOPHARMA INC | $57.41 | 2 |
| Janssen Pharmaceuticals, Inc | $54.04 | 1 |
| Janssen Biotech, Inc. | $54.03 | 3 |
| Celgene Corporation | $52.60 | 3 |
| Sumitomo Pharma America, Inc. | $46.93 | 2 |
| Merck Sharp & Dohme Corporation | $45.91 | 2 |
| Janssen Scientific Affairs, LLC | $42.11 | 1 |
| PFIZER INC. | $37.60 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $30.31 | 1 |
| SOBI, INC | $29.08 | 1 |
| EISAI INC. | $26.44 | 1 |
| Karyopharm Therapeutics Inc. | $25.78 | 1 |
| Regeneron Healthcare Solutions, Inc. | $25.29 | 1 |
| GlaxoSmithKline, LLC. | $24.95 | 1 |
| ABBVIE INC. | $23.15 | 1 |
| Stemline Therapeutics Inc. | $22.93 | 1 |
| TAIHO ONCOLOGY, INC. | $21.44 | 1 |
| Amgen Inc. | $21.20 | 1 |
| Lilly USA, LLC | $19.89 | 1 |
| JAZZ PHARMACEUTICALS INC. | $19.76 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $16.47 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (58)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.